The dose you are given on day one is chosen to be safe to start, not to be the dose that works. Titration — the structured process of adjusting it — is where the actual treatment decision gets made, and it is the part people most often abandon before reaching the end of.
What the starting dose is for
The first dose establishes tolerance. It is not an attempt at the right amount, and it is not a test the medication can fail.
CHADD puts the standard plainly: treatment usually starts with a low dose that is adjusted gradually based on symptom improvement and side effects. The starting point is deliberately the bottom of a range that is expected to be walked upward.
NICE is explicit about why no dose can be correct in advance: effect size, duration of effect and adverse effects all vary from person to person. There is no way to know your numbers without measuring them on you.
This is the mechanism behind a very common conclusion. People decide medication does not work for them using information gathered at a dose nobody expected to work yet.
What “the right dose” is actually defined as
NICE gives the endpoint a definition, and it is worth reading closely. Titrate against symptoms and adverse effects until dose optimisation is achieved — that is, reduced symptoms, positive behaviour change, improvements in education, employment and relationships, with tolerable adverse effects.
Two things in that are easy to miss.
It is four measures, not one. Symptoms are only the first. Whether anything changed in your work, your studying, or the people around you counts as part of the target rather than a bonus.
And the word is tolerable, not absent. The endpoint is a balance point: the most benefit available at a level of side effects you can live with. A dose that removes every symptom and stops you sleeping has not hit the target.
That definition is useful to you because it gives you something specific to report against.
Titration is measured, not felt
NICE builds recording into the process: during titration, symptoms, impairment and adverse effects should be recorded at baseline and at each dose change on standard scales, with progress reviewed regularly — for example by weekly telephone contact with a specialist.
Baseline is the part people skip, and it is the part that matters most. Without a record from before you started, you are comparing against your memory of how you were functioning — which is the single least reliable instrument available for this particular job. Not noticing that you have drifted is itself part of the executive function picture being treated.
The guideline also asks prescribers to encourage people to monitor and record their own adverse effects, using something like an adverse effect checklist. Side effects are treated as expected data, collected on purpose — not as evidence that something has gone wrong.
What is worth writing down
Keep it short enough that you will actually do it. A few lines a day is more useful than a system you abandon in week two.
- One or two specific, repeatable tasks. Not “was I focused” but: did I start the thing, and how long did it take me to start it.
- When the effect began and when it faded. This is the measurement that answers the most questions later.
- Sleep. What time you actually fell asleep, not what time you went to bed. Sleep is where stimulant effects show up first, and it is easy to lose track of separately from the reasons you were already going to bed late.
- Appetite. Simply whether you ate lunch. A yes or no is enough.
- Side effects as they occur. CHADD lists the common ones for stimulants as trouble sleeping, dry mouth, headaches, decreased appetite, increased heart rate and increased blood pressure.
Duration deserves its own line because it is so often misread. CHADD gives short-acting stimulants as roughly four hours, and long-acting forms as six to eight hours or all day. If something works well and then stops at one in the afternoon, that is information about formulation and timing. It is not a medication that failed.
When titration is supposed to go slower
NICE directs that dose titration be slower and monitoring more frequent where any of the following are present:
- Neurodevelopmental conditions — for example autism spectrum disorder, tic disorders, learning disability.
- Mental health conditions — for example anxiety disorders including obsessive–compulsive disorder, schizophrenia or bipolar disorder, depression, personality disorder, eating disorder, post-traumatic stress disorder, substance misuse.
- Physical health conditions — for example cardiac disease, epilepsy or acquired brain injury.
That list covers a great many people, because conditions of this kind commonly occur alongside ADHD. If your titration is moving slowly and one of these applies, that is the guideline being followed correctly rather than you being deprioritised.
Who is supposed to be running it
In the UK, NHS guidance is that ADHD medicines must be started and monitored by an ADHD specialist. NICE then sets out what happens afterwards: once titration and dose stabilisation are complete, prescribing and monitoring move to shared care arrangements with primary care.
So the intensive, closely monitored phase is meant to be specialist-led and finite. It is a distinct stage with an end, not the permanent condition of being medicated.
Common questions
How long does titration take?
We are not going to give you a number. Figures circulate widely, and we could not trace the common one to a primary source, so it is left out. What is defined is the endpoint — dose optimisation as described above — and the monitoring cadence, which NICE illustrates as regular review such as weekly contact. Titration ends when the target is met, not on a date set in advance.
Is it a bad sign if the first medication does not suit me?
No, and it is anticipated. NHS guidance notes that people may need to try more than one medicine to find what works for them. A medication that does not suit you is a result, and it narrows the search.
Should I stop if side effects appear?
Record them and report them rather than deciding alone. The whole structure assumes side effects will appear and get logged at each dose change — that is why the checklist exists. Anything involving your heart, your breathing or your mood needs to be raised promptly rather than at the next scheduled review.
It works, then wears off mid-afternoon. Is that the wrong drug?
Not necessarily — it is more often a duration question. NICE explicitly contemplates using a modified-release preparation in the morning together with an immediate-release preparation later in the day, specifically to extend the duration of effect. This is a known problem with a known set of answers, and it is worth describing precisely to your prescriber: what time it starts, what time it stops.
What if I cannot tell whether it is working?
That usually means there is no baseline to compare against, which is fixable going forward but not retrospectively. Start recording now, and ask whether anyone around you has noticed a change — an outside observation is a legitimate data point, and NICE counts improvements in work and relationships as part of the target.
Related reading
- Adult ADHD Diagnosis: What to Expect
- ADHD Task Paralysis: Why Starting Is the Hardest Part
- Executive Function and ADHD: The Complete Guide
- ADHD Time Blindness: The Complete Guide
- Revenge Bedtime Procrastination and ADHD
Sources
- NICE, Attention deficit hyperactivity disorder: diagnosis and management (NG87), Recommendations — dose titration and recording at each dose change (1.7.26), the definition of dose optimisation (1.7.27), slower titration where other conditions are present (1.7.28), variation between people and combining preparations to extend duration (1.7.21, 1.7.22), shared care after stabilisation (1.7.29), and self-monitoring of adverse effects (1.8.2)
- CHADD, Using Medication to Manage ADHD Symptoms — starting at a low dose adjusted gradually, duration of short-acting and long-acting stimulants, and common side effects
- NHS, ADHD treatment — medicines started and monitored by an ADHD specialist, and that more than one medicine may need to be tried
- National Institute of Mental Health, ADHD — standard treatment combines medication with psychosocial interventions
Inchy publishes general information, not medical advice. Decisions about starting, adjusting or stopping medication belong with the clinician prescribing it, who can consider your full situation. If you are having a bad reaction to a medicine, contact your prescriber or seek urgent medical help. See our editorial policy.